Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005469 | 0.88 | SMN1; SMN2 (0.73) | SMN1; SMN2CYP2C19CYP3A4CYP2D6TOP2A | |
| SCHEMBL19700231 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2C19MAPTCYP1A2ALDH1A1 | |
| SCHEMBL10279786 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP2C19CYP2D6FAAHMAPT | |
| SCHEMBL10290969 | 0.81 | NPC1 (0.43) | SMN1; SMN2CYP2C19CYP3A4CYP2D6NPC1 | |
| SCHEMBL22570217 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP2C19CYP3A4CYP2D6TOP2A | |
| SCHEMBL13125414 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP2C19CYP3A4CYP2D6NPC1 | |
| SCHEMBL511990 | 0.76 | FAAH (0.41) | CYP2C19CYP3A4CYP2D6NPC1FAAH | |
| SCHEMBL10014920 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2C19MAPTCYP1A2ALDH1A1 | |
| SCHEMBL14087052 | 0.75 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP2C19FAAHMAPTCYP1A2 | |
| SCHEMBL361963 | 0.75 | MAPT (0.43) | CYP2C19MAPTCYP1A2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2459197-B1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2015-06-04 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2459197-A1 | COMPOUNDS FOR THE REDUCTION OF -AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
| US-20150152089-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
| US-20130178462-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
| US-20150336975-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | SMN1; SMN2 760/4885CYP2C19 4099/4885CYP3A4 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.